

BIOTECHNOLOGY FUND

	SHARES	VALUE
COMMON STOCKS† - 99.8%		
BIOTECHNOLOGY - 63.9%		
Amgen, Inc.	120,899	\$ 22,541,620
Celgene Corp.*	147,479	21,505,389
Gilead Sciences, Inc.	246,365	19,960,493
Biogen, Inc.*	49,475	15,491,613
Regeneron Pharmaceuticals, Inc.*	33,512	14,983,885
Vertex Pharmaceuticals, Inc.*	83,387	12,678,159
Alexion Pharmaceuticals, Inc.*	78,962	11,077,579
Illumina, Inc.*	51,697	10,298,042
Incyte Corp.*	85,917	10,029,951
Alnylam Pharmaceuticals, Inc.* ¹	72,271	8,491,120
BioMarin Pharmaceutical, Inc.*	84,762	7,888,799
Kite Pharma, Inc.*	32,534	5,849,939
Seattle Genetics, Inc.*	101,027	5,496,879
Exelixis, Inc.*	214,167	5,189,266
Bio-Rad Laboratories, Inc. — Class A*	23,182	5,151,504
Bioverativ, Inc.*	89,547	5,110,447
Exact Sciences Corp.*	108,444	5,109,881
United Therapeutics Corp.*	39,946	4,681,272
Charles River Laboratories International, Inc.*	43,218	4,668,408
Bluebird Bio, Inc.*	33,220	4,562,767
Ionis Pharmaceuticals, Inc.*	86,641	4,392,699
Puma Biotechnology, Inc.*	35,210	4,216,398
Spark Therapeutics, Inc.*	43,020	3,835,663
Prothena Corporation plc ¹	58,533	3,791,182
Medicines Co.* ¹	101,908	3,774,672
Juno Therapeutics, Inc.*	83,350	3,739,081
Sage Therapeutics, Inc.*	54,620	3,402,826
Ligand Pharmaceuticals, Inc. — Class B* ¹	24,635	3,354,055
Myriad Genetics, Inc.*	89,596	3,241,583
Halozyme Therapeutics, Inc.*	176,675	3,068,845
Intrexon Corp.* ¹	159,720	3,036,277
Ultragenyx Pharmaceutical, Inc.*	57,006	3,036,140
Esperion Therapeutics, Inc.*	45,837	2,297,350
Five Prime Therapeutics, Inc.*	56,031	2,292,228
Acorda Therapeutics, Inc.*	96,491	2,282,012
Intercept Pharmaceuticals, Inc.* ¹	39,060	2,267,042
Accelaron Pharma, Inc.*	59,660	2,226,511
Dynavax Technologies Corp.*	99,800	2,145,700
AMAG Pharmaceuticals, Inc.*	76,401	1,409,598
Total Biotechnology		258,576,875
PHARMACEUTICALS - 29.8%		
AbbVie, Inc.	249,634	22,182,477
Shire plc ADR	86,180	13,197,605
TESARO, Inc.*	46,513	6,004,828
Jazz Pharmaceuticals plc*	34,060	4,981,275
Neurocrine Biosciences, Inc.*	78,221	4,793,383
Alkermes plc*	93,978	4,777,842
PRA Health Sciences, Inc.*	60,730	4,625,804
Clovis Oncology, Inc.*	55,900	4,606,160
ACADIA Pharmaceuticals, Inc.*	113,108	4,260,778
Akorn, Inc.*	125,093	4,151,837
Avexis, Inc.* ¹	40,440	3,911,761
Nektar Therapeutics*	160,647	3,855,528
Portola Pharmaceuticals, Inc.*	67,835	3,665,125
Agios Pharmaceuticals, Inc.*	52,248	3,487,554
Amicus Therapeutics, Inc.* ¹	224,610	3,387,119
Horizon Pharma plc*	247,636	3,140,024
Sarepta Therapeutics, Inc.*	68,900	3,125,304
Radius Health, Inc.* ¹	79,393	3,060,600
Ironwood Pharmaceuticals, Inc. — Class A*	193,501	3,051,511
Array BioPharma, Inc.*	247,150	3,039,945
Global Blood Therapeutics, Inc.*	85,875	2,666,419
Pacira Pharmaceuticals, Inc.*	65,540	2,461,027
Impax Laboratories, Inc.*	113,707	2,308,252
Heron Therapeutics, Inc.* ¹	132,650	2,142,298
Eagle Pharmaceuticals, Inc.* ¹	32,160	1,918,022
Cara Therapeutics, Inc.* ¹	100,700	1,378,583
Total Pharmaceuticals		120,181,061
HEALTHCARE-PRODUCTS - 2.6%		
Bio-Techne Corp.	35,452	4,285,792
QIAGEN N.V.*	120,517	3,796,286
MiMedx Group, Inc.* ¹	200,575	2,382,831
Total Healthcare-Products		10,464,909
HEALTHCARE-SERVICES - 2.3%		
Quintiles IMS Holdings, Inc.*	99,644	9,473,155
COMMERCIAL SERVICES - 1.2%		
Incorporated Research Holdings, Inc. — Class A*	91,710	4,796,433
Total Common Stocks (Cost \$234,323,789)		403,492,433
RIGHTS††† - 0.0%		
Chelsea Therapeutics International Expires 12/31/17* ⁵	231,107	—
Dyax Corp. Expires 01/25/18* ⁵	167,165	—
Clinical Data, Inc. Expires 12/31/20* ⁵	24,000	—
Total Rights (Cost \$17,304)		—

BIOTECHNOLOGY FUND

	FACE AMOUNT	VALUE
REPURCHASE AGREEMENTS^{††,2} - 0.2%		
BNP Paribas issued 09/29/17 at 1.00% due 10/02/17	\$ 308,553	\$ 308,553
Bank of America Merrill Lynch issued 09/29/17 at 1.05% due 10/02/17	154,277	154,277
HSBC Securities, Inc. issued 09/29/17 at 0.91% due 10/02/17	154,158	154,158
Total Repurchase Agreements (Cost \$616,988)		616,988
	SHARES	
SECURITIES LENDING COLLATERAL^{†,3} - 5.7%		
First American Government Obligations Fund — Class Z, 0.89% ⁴	22,839,008	22,839,008
Total Securities Lending Collateral (Cost \$22,839,008)		22,839,008
Total Investments - 105.7% (Cost \$257,797,089)		\$ 426,948,429
Other Assets & Liabilities, net - (5.7)%		(23,196,103)
Total Net Assets - 100.0%		\$ 403,752,326

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

¹ All or portion of this security is on loan at September 30, 2017.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7 day yield as of September 30, 2017.

⁵ Security was fair valued by the valuation committee at September 30, 2017. The total market value of fair valued securities amounts to \$0, (cost \$17,304) or 0.0% of total net assets.

ADR — American Depositary Receipt

plc — Public Limited Company